BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 9, 2004
View Archived Issues
New modulators of farnesoid X receptors covered by X-Ceptor patent
Read More
Novel FAP-activated prodrugs with utility in cancer therapy
Read More
Kowa describes new PPARalpha agonists, their preparation and use
Read More
Yamanouchi patents novel ApoB-related lipoprotein secretion inhibitors
Read More
Bayer scientists claim new pyrimidine-based antiproliferative agents
Read More
Update on Generex technologies
Read More
Enrollment stopped in phase II of Velcade for metastatic colorectal cancer
Read More
FDA approval for Invirase boosted with ritonavir for HIV
Read More
Restructuring at D-Pharm completed
Read More
GT-1061 advances into phase I safety study for Alzheimer's
Read More
U.S. enrollment commences for phase II SDX-105 study
Read More
BCY Lifesciences seeking partner or licensee for DCF-987
Read More
Zavesca launched in U.S.
Read More
Dosing commences in pivotal PRECIS-1 study of CDP-870 for Crohn's disease
Read More
Chemokine Therapeutics files for U.S. orphan drug designation for CTCE-9908
Read More
Andrx and Takeda to develop Actos/Fortamet combination product
Read More
Organon pays Cortex milestone to retain AMPAKINE technology rights
Read More
Long-term effectiveness of olanzapine and haloperidol in schizophrenia
Read More
ISV-205 limits IOP increase induced by corticosteroids
Read More
Long-term use of lipid-lowering drugs reported to improve when started in an inpatient setting
Read More
A new phase II clinical trial to evaluate two furosemide formulations in CHF patients
Read More
Oxycyte(TM) to enter phase II testing during 2004
Read More
Tularik's T-131 is being assessed in patients with type 2 diabetes
Read More
Dynogen Pharmaceuticals announces collaboration with Johnson & Johnson
Read More
Corixa Corporation announces NIH biodefense partnership
Read More
Aventis Pharma and Avalon Pharmaceuticals form collaboration
Read More
XenoPort announces collaboration with Pfizer
Read More
PCALC-36, a new Na+/K+-ATPase inhibitor with a unique mechanism of action
Read More
Primaquine derivative shows good antimalarial activity and less toxicity
Read More